Genelux Corporation

GNLX | NASDAQ

Price Alert Chart Builder DCF Calculator

$2.55

-$0.01 (-0.39%)

Sep 22, 2026, 9:33 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.39%

(1D)

Rating

Updated: Sep 7, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $114.34M

1D Range

2.55 2.55

52W Range

2.29 8.54

Valuation (TTM)

PE -2.88

PB 7.12

EV/EBITDA -2.87

Valuation (NTM)

Forward PE N/A

Forward PEG 0.37

Price Target $17.33

Cash Flow

FCF Yield -25.0%

SBC Adj. FCF Yield -31.1%

SBC Impact -24.7%

Margins

Gross Margin -1762.5%

Operating Margin -445200.0%

FCF Margin -358537.5%

Growth (CAGR)

Revenue 3Y | 5Y -91.1% | -49.9%

Dil EPS 3Y | 5Y 3.9% | -11.4%

FCF 3Y | 5Y -13.1% | -35.8%

Returns

ROA -129.0%

ROE -195.4%

ROIC -192.2%

Financial Health

Net Cash

$16.25M

Current Ratio 2.39

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor ma...

Sector Healthcare

Industry Biotechnology

Employees 26

IPO Date Jan 25, 2023

Website www.genelux.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

$16

Upside

+527.45%

Buy (0)

Hold (0)

Sell (0)

Analyst Details ➞